Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1Abatacept, rituximab or tocilizumab
(D02596)		1件: Abatacept1件: Abatacept 💬 2件: CD80,
CD86 💬 		13件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬1件: 46 💬
2Adalimuab, etanercept, tocilizumab, or abatacept
(D02596)		----1件: 46 💬
3Corticoids+ tocilizumab 8MG/KG/4 weeks
(D02596)		----1件: 41 💬
4Decrease tocilizumab, abatacept
(D02596)		2件: Abatacept,
Tocilizumab		2件: Tocilizumab (D02596),
Abatacept 💬 		3件: CD80,
CD86,
IL6R 💬 		24件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Rheumatoid arthritis, Systemic lupus erythematosus, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Viral protein interaction with cytokine and cytokine receptor, Virion - Adenovirus 💬1件: 46 💬
5Etanercepet, rituximab, abatacept, tocilizumab, sarilumab
(D02596)		4件: Abatacept,
Rituximab,
Sarilumab,
Tocilizumab		4件: Tocilizumab (D02596),
Rituximab ,
Abatacept ,
Sarilumab 💬 		4件: CD80,
CD86,
IL6R,
MS4A1 💬 		24件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Rheumatoid arthritis, Systemic lupus erythematosus, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Viral protein interaction with cytokine and cytokine receptor, Virion - Adenovirus 💬1件: 46 💬
6INN-tocilizumab
(D02596)		1件: Tocilizumab1件: Tocilizumab (D02596) 💬 1件: IL6R 💬 11件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 266 💬
7Intra-articular tocilizumab
(D02596)		----1件: 46 💬
8Subcutaneous tocilizumab
(D02596)		----1件: 46 💬
9Subcutaneous tocilizumab 162MG/biweekly
(D02596)		----1件: 46 💬
10Tocilizumab
(D02596)		1件: Tocilizumab1件: Tocilizumab (D02596) 💬 1件: IL6R 💬 11件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬24件: 2, 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 149, 153, 266, 271, 298, 331 💬
11Tocilizumab 162 MG
(D02596)		1件: Tocilizumab1件: Tocilizumab (D02596) 💬 1件: IL6R 💬 11件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 46 💬
12Tocilizumab 162MG/0.9ML autoinjector
(D02596)		1件: Tocilizumab1件: Tocilizumab (D02596) 💬 1件: IL6R 💬 11件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 41 💬
13Tocilizumab 162MG/0.9ML jeringa SC
(D02596)		1件: Tocilizumab1件: Tocilizumab (D02596) 💬 1件: IL6R 💬 11件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 46 💬
14Tocilizumab 162MG/0.9ML SC PFS SC
(D02596)		1件: Tocilizumab1件: Tocilizumab (D02596) 💬 1件: IL6R 💬 11件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 46 💬
15Tocilizumab 162MG/0.9ML syringe SC
(D02596)		1件: Tocilizumab1件: Tocilizumab (D02596) 💬 1件: IL6R 💬 11件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 46 💬
16Tocilizumab and IV steroids combination
(D02596)		1件: Tocilizumab1件: Tocilizumab (D02596) 💬 1件: IL6R 💬 11件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 41 💬
17Tocilizumab injectable product
(D02596)		1件: Tocilizumab1件: Tocilizumab (D02596) 💬 1件: IL6R 💬 11件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 11 💬
18Tocilizumab injection
(D02596)		1件: Tocilizumab1件: Tocilizumab (D02596) 💬 1件: IL6R 💬 11件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬2件: 11, 13 💬
19Tocilizumab injection 8MG/KG
(D02596)		1件: Tocilizumab1件: Tocilizumab (D02596) 💬 1件: IL6R 💬 11件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 46 💬
20Tocilizumab IV
(D02596)		1件: Tocilizumab1件: Tocilizumab (D02596) 💬 1件: IL6R 💬 11件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 46 💬
21Tocilizumab or sarilumab
(D02596)		2件: Sarilumab,
Tocilizumab		2件: Tocilizumab (D02596),
Sarilumab 💬 		1件: IL6R 💬 11件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 46 💬
22Tocilizumab plus methotrexate
(D02596)		2件: Methotrexate,
Tocilizumab		3件: Methotrexate ,
Methotrexate sodium ,
Tocilizumab (D02596) 💬 		3件: DHFR,
DHFR,
IL6R 💬 		14件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Folate biosynthesis, Folate transport and metabolism, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, One carbon pool by folate, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 46 💬
23Tocilizumab prefilled syringe
(D02596)		1件: Tocilizumab1件: Tocilizumab (D02596) 💬 1件: IL6R 💬 11件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬2件: 41, 46 💬
24Tocilizumab roche
(D02596)		1件: Tocilizumab1件: Tocilizumab (D02596) 💬 1件: IL6R 💬 11件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬2件: 46, 107 💬
25Tocilizumab SC
(D02596)		1件: Tocilizumab1件: Tocilizumab (D02596) 💬 1件: IL6R 💬 11件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬3件: 41, 46, 107 💬
26Tocilizumab treatment
(D02596)		1件: Tocilizumab1件: Tocilizumab (D02596) 💬 1件: IL6R 💬 11件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 41 💬